Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.
The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells.
The company has a research collaboration agreement with CRISPR Therapeutics AG.
Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 24 | -0.58 Increased by +7.94% | -0.56 Decreased by -3.57% |
| Mar 21, 24 | -0.57 Increased by +14.93% | -0.59 Increased by +3.39% |
| Nov 9, 23 | -0.52 Increased by +10.34% | -0.67 Increased by +22.39% |
| Aug 10, 23 | -0.60 Increased by +1.64% | -0.68 Increased by +11.76% |
| May 11, 23 | -0.63 Increased by +20.25% | -0.70 Increased by +10.00% |
| Mar 16, 23 | -0.67 Increased by +2.90% | -0.64 Decreased by -4.69% |
| Nov 9, 22 | -0.58 Increased by +14.71% | -0.62 Increased by +6.45% |
| Aug 11, 22 | -0.61 Increased by +7.58% | -0.59 Decreased by -3.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -25.64 M Increased by +2.96% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -33.29 M Decreased by -20.57% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -27.32 M Decreased by -4.67% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -35.47 M Decreased by -55.48% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -26.43 M Decreased by -18.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -27.61 M Decreased by -28.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -26.10 M Decreased by -34.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -22.81 M Decreased by -27.47% | Decreased by N/A% Decreased by N/A% |